NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TherapeuticsMD Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.67 +0.06 (+3.73 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$1.63Now: $1.67▼$1.7350-Day Range$1.17MA: $1.59▼$2.2452-Week Range$0.85Now: $1.67▼$4.32Volume4.98 million shsAverage Volume5.98 million shsMarket Capitalization$453.71 millionP/E RatioN/ADividend YieldN/ABeta2.33 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingTherapeuticsMD has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.53, TherapeuticsMD has a potential upside of 351.1% from its current price of $1.67.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesTherapeuticsMD has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTherapeuticsMD has received 332 “underperform” votes. (Add your “underperform” vote.)Community SentimentTherapeuticsMD has received 52.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote “Outperform” if you believe TXMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,331.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 13.76% of the stock of TherapeuticsMD is held by insiders.Percentage Held by Institutions67.02% of the stock of TherapeuticsMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TherapeuticsMD are expected to grow in the coming year, from ($0.60) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 55.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.10 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone561-961-1900Debt Debt-to-Equity Ratio22.15 Current Ratio3.44 Quick Ratio3.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$49.65 million Price / Sales9.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book55.67Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-176,150,000.00 Net Margins-304.01% Return on Equity-1,170.63% Return on Assets-70.66%Miscellaneous Employees348 Outstanding Shares271,680,000Market Cap$453.71 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.67 +0.06 (+3.73 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions How has TherapeuticsMD's stock been impacted by COVID-19 (Coronavirus)? TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TXMD stock has increased by 9.9% and is now trading at $1.67. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TherapeuticsMD? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for TherapeuticsMD. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. TherapeuticsMD had a negative return on equity of 1,170.63% and a negative net margin of 304.01%. View TherapeuticsMD's earnings history. What price target have analysts set for TXMD? 7 brokers have issued 1 year price objectives for TherapeuticsMD's shares. Their forecasts range from $1.20 to $15.00. On average, they expect TherapeuticsMD's stock price to reach $7.53 in the next year. This suggests a possible upside of 351.1% from the stock's current price. View analysts' price targets for TherapeuticsMD. Has TherapeuticsMD been receiving favorable news coverage? News headlines about TXMD stock have trended very positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about TherapeuticsMD. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include I-Mab (IMAB), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), INDIVIOR PLC/S (INVVY), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intercept Pharmaceuticals (ICPT), MacroGenics (MGNX), Dicerna Pharmaceuticals (DRNA), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), Zymeworks (ZYME) and Portola Pharmaceuticals (PTLA). View all competitors. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), Cleveland-Cliffs (CLF), NVIDIA (NVDA), CannTrust (CNTTF), Micron Technology (MU), Horizon Therapeutics (HZNP) and Novavax (NVAX). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the following people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 49, Pay $1.22M)Mr. John C. K. Milligan IV, Pres & Sec. (Age 58, Pay $794.68k)Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 62, Pay $659.3k)Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 54, Pay $560.53k)Mr. Michael Donegan, VP of Fin. (Age 52, Pay $378.3k) What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by a number of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (1.37%), Swiss National Bank (0.21%), SG Americas Securities LLC (0.15%), Raymond James Financial Services Advisors Inc. (0.15%), UBS Group AG (0.04%) and Principal Financial Group Inc. (0.04%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View institutional ownership trends for TherapeuticsMD. Which institutional investors are selling TherapeuticsMD stock? TXMD stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, and Sanders Morris Harris LLC. View insider buying and selling activity for TherapeuticsMD. Which institutional investors are buying TherapeuticsMD stock? TXMD stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., SG Americas Securities LLC, Swiss National Bank, Principal Financial Group Inc., Virtu Financial LLC, UBS Group AG, ProShare Advisors LLC, and Wedbush Securities Inc.. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson. View insider buying and selling activity for TherapeuticsMD. How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $1.67. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $453.71 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 348 workers across the globe. What is TherapeuticsMD's official website? The official website for TherapeuticsMD is www.therapeuticsmd.com. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
